[go: up one dir, main page]

DE69623264D1 - Verfahren zur diagnose gutartiger prostataerkrankungen - Google Patents

Verfahren zur diagnose gutartiger prostataerkrankungen

Info

Publication number
DE69623264D1
DE69623264D1 DE69623264T DE69623264T DE69623264D1 DE 69623264 D1 DE69623264 D1 DE 69623264D1 DE 69623264 T DE69623264 T DE 69623264T DE 69623264 T DE69623264 T DE 69623264T DE 69623264 D1 DE69623264 D1 DE 69623264D1
Authority
DE
Germany
Prior art keywords
patient
psa
proportion
level
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69623264T
Other languages
English (en)
Other versions
DE69623264T2 (de
Inventor
Albert A Luderer
Grant D Carlson
Robert P Thiel
Thomas F Soriano
William J Kramp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69623264D1 publication Critical patent/DE69623264D1/de
Application granted granted Critical
Publication of DE69623264T2 publication Critical patent/DE69623264T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69623264T 1995-02-23 1996-02-21 Verfahren zur diagnose gutartiger prostataerkrankungen Expired - Lifetime DE69623264T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/393,214 US5698402A (en) 1995-02-23 1995-02-23 Methods for diagnosing benign prostatic hyperplasia
US393214 1995-02-23
PCT/US1996/003045 WO1996026441A1 (en) 1995-02-23 1996-02-21 Novel methods for diagnosing benign prostatic diseases

Publications (2)

Publication Number Publication Date
DE69623264D1 true DE69623264D1 (de) 2002-10-02
DE69623264T2 DE69623264T2 (de) 2004-01-22

Family

ID=23553761

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69623264T Expired - Lifetime DE69623264T2 (de) 1995-02-23 1996-02-21 Verfahren zur diagnose gutartiger prostataerkrankungen

Country Status (7)

Country Link
US (3) US5698402A (de)
EP (2) EP1221619A3 (de)
JP (1) JP2001503129A (de)
AT (1) ATE223051T1 (de)
CA (1) CA2213709C (de)
DE (1) DE69623264T2 (de)
WO (1) WO1996026441A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5698402A (en) * 1995-02-23 1997-12-16 Dianon Systems, Inc. Methods for diagnosing benign prostatic hyperplasia
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
NZ333235A (en) 1996-06-17 2000-06-23 Guilford Pharm Inc Methods of cancer treatment using naaladase inhibitors
US6046180A (en) * 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US5840501A (en) * 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
IL121659A (en) * 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en) * 1998-03-30 2000-09-19 Guilford Pharmaceuticals Inc. Phosphinic acid derivatives
AU3590199A (en) * 1998-05-01 1999-11-23 Queen's University At Kingston Method for diagnosing a vascular condition
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
KR100672965B1 (ko) 1998-07-06 2007-02-28 길포드 파마슈티컬스 인코포레이티드 약제학적 화합물로 유용한 나알라다제 억제제 및 그의조성물
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
JP4495349B2 (ja) * 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド 癌の遺伝マーカーを生物学的サンプルにおいて検出するための核酸配列
EP1178317B1 (de) 2000-07-24 2004-11-10 Health Research, Inc. Verfahren zur Detektion von Prostata-spezifischem Membran-Antigen in Serum
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
WO2002027316A2 (en) * 2000-09-25 2002-04-04 Abbott Laboratories Methods and kits for decreasing interferences of assays samples containing plasma or serum in specific binding assays by using a large polycation
US20050037447A1 (en) * 2003-07-08 2005-02-17 Yong-Chuan Wong Protein markers for human benign prostatic hyperplasia (BPH)
US20060194230A1 (en) * 2005-01-25 2006-08-31 Baylor College Of Medicine Genetic markers associated with benign prostatic hyperplasia
EP3410118B1 (de) * 2016-01-27 2020-09-30 FUJIFILM Wako Pure Chemical Corporation Verfahren zur bestimmung eines prostatakarzinoms
US10585101B2 (en) * 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia
ES2688213T3 (es) 2016-07-15 2018-10-31 Proteomedix Ag Método para detectar proteínas en muestras humanas y usos de dichos métodos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0635575A1 (de) * 1993-07-22 1995-01-25 Wallac Oy Monoklonale Antikörper gegen Epitope in freiem uber nicht in Alpha-1-antichymotrypsin komplexiertem Prostata spezifisches Antigen
US5698402A (en) * 1995-02-23 1997-12-16 Dianon Systems, Inc. Methods for diagnosing benign prostatic hyperplasia
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma

Also Published As

Publication number Publication date
EP1221619A2 (de) 2002-07-10
EP0811162A1 (de) 1997-12-10
US5912135A (en) 1999-06-15
EP0811162B1 (de) 2002-08-28
CA2213709A1 (en) 1996-08-29
JP2001503129A (ja) 2001-03-06
US5698402A (en) 1997-12-16
US6100049A (en) 2000-08-08
EP0811162A4 (de) 1999-09-01
WO1996026441A1 (en) 1996-08-29
CA2213709C (en) 2009-01-27
MX9706415A (es) 1998-07-31
ATE223051T1 (de) 2002-09-15
EP1221619A3 (de) 2002-08-07
DE69623264T2 (de) 2004-01-22

Similar Documents

Publication Publication Date Title
DE69623264D1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
DE69937368D1 (de) Nachweis von erkrankungen der nieren und behandlung
DE59705683D1 (de) IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
Baydanoff et al. Age-related changes in the level of circulating elastin-derived peptides in serum from normal and atherosclerotic subjects
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
ATE154613T1 (de) Monoklonaler antikörper spezifisch für ein humanes atherom-assoziiertes antigen
ATE68600T1 (de) Satz und verfahren zur diagnose der iganephropathie.
NO953770L (no) Analysemetode
DE69900998D1 (de) Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse
DE69712079D1 (de) Diagnostisches verfahren für atherosklerosis
NZ531712A (en) Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
DE69605908D1 (de) Benutzung von reagenzien abgeleitet vom menschlichen metastase unterdrückungs gen kai1 in diagnostischen und gen-terapeutischen verfahren
ATE217089T1 (de) Diagnostisches verfahren für atherosklerosis
HUP0003684A2 (hu) Alzheimer-kór diagnosztizálására szolgáló vizsgálat
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
DE50007635D1 (de) Verfahren zur diagnose von sjögren-syndrom
ATE326698T1 (de) Immunologisches test und satz zur diagnose von prostatadenokarzinom
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
ATE382678T1 (de) Verfahren zur diagnose von rickettsia pulicis
JPH07135973A (ja) 歯周病原性菌由来酵素およびその測定方法並びに当該酵素に対する抗体
CA2332310A1 (en) Antibody against protein tyrosine phosphatase intracellular domains
DE59510686D1 (de) Komplexverbindungen zur diagnose von gefässerkrankungen
ES2099876T3 (es) Procedimiento para la determinacion de anticuerpos de lupus anticoagulante que provocan trombosis.
ATE554790T1 (de) Verfahren und zusammensetzungen zur diagnose von asthma

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition